Showing results (751-760 of 1,192) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|August 30, 2020
A stochastically curtailed two-arm randomised phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P ManderPharmaceutical Statistics|March 22, 2020
The attributable estimand: A new approach to account for intercurrent eventsPatrick Darken, Jack Nyberg, Shaila Ballal, et al.Pharmaceutical Statistics|April 1, 2020
Incorporating historical two-arm data in clinical trials with binary outcome: A practical approachManuel Feißt, Johannes Krisam, Meinhard KieserPharmaceutical Statistics|October 7, 2020
TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapyYan Han, Hao Liu, Sha Cao, et al.Pharmaceutical Statistics|April 1, 2018
Better decision making in drug development through adoption of formal prior elicitationNigel Dallow, Nicky Best, Timothy H MontaguePharmaceutical Statistics|December 1, 2020
Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trialsAmi Takahashi, Taiji SuzukiPharmaceutical Statistics|October 29, 2020
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysisMark Rothmann, William Crown, Thomas A Louis, et al.Pharmaceutical Statistics|November 23, 2020
Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure modelsLu Yang, Hui Song, Yingwei Peng, et al.Pharmaceutical Statistics|February 21, 2018
Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myelomaSamer A Kharroubi, Richard Edlin, David Meads, et al.Pharmaceutical Statistics|September 4, 2014
A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trialsJiwei He, Richard EntsuahPageof 120